SCHEMBL1011398

SCHEMBL1011398

FC(F)(F)c1ccc(Oc2cccc(Br)c2)nc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.72
MAPK1 P28482 1/20 0.67
L3MBTL1 Q9Y468 3/20 0.54
POLB P06746 2/20 0.54
ALDH1A1 P00352 1/20 0.54
TSHR P16473 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
MAPT P10636 2/20 0.50
KMT2A Q03164 1/20 0.50
GAA P10253 1/20 0.49
NPSR1 Q6W5P4 2/20 0.49
LMNA P02545 1/20 0.48
HPGD P15428 1/20 0.48
RAB9A P51151 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
ATM Q13315 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1417238 0.86 THRB (0.69) THRBMAPK1L3MBTL1POLBALDH1A1
SCHEMBL6531818 0.82 MAPK1 (0.75) THRBMAPK1L3MBTL1POLBALDH1A1
SCHEMBL5651111 0.82 MAPK1 (0.67) THRBMAPK1L3MBTL1POLBALDH1A1
SCHEMBL10500983 0.82 MAPK1 (0.67) THRBMAPK1L3MBTL1POLBALDH1A1
SCHEMBL20381754 0.82 MAPK1 (0.71) THRBMAPK1L3MBTL1POLBALDH1A1
SCHEMBL30334879 0.82 MAPK1 (0.67) THRBMAPK1L3MBTL1POLBALDH1A1
SCHEMBL31360505 0.82 THRB (0.49) THRBMAPK1L3MBTL1POLBALDH1A1
SCHEMBL9272113 0.81 THRB (0.76) THRBMAPK1L3MBTL1TSHRSMN1; SMN2
SCHEMBL1011707 0.81 THRB (0.63) THRBMAPK1L3MBTL1POLBALDH1A1
SCHEMBL9507549 0.81 MAPK1 (0.64) THRBMAPK1L3MBTL1POLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044052-B2 Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis PFIZER INC. (US) 2011-10-25 US disclosed
EP-2076508-B1 BIARYL ETHER UREA COMPOUNDS PFIZER PROD INC (US) 2011-01-05 EP disclosed
EP-2076508-A2 BIARYL ETHER UREA COMPOUNDS Pfizer Products Inc. (US) 2009-07-08 EP disclosed
US-20080261941-A1 Biaryl Ether Urea Compounds Jazz Pharmaceuticals Therapeutics, Inc. 2008-10-23 US disclosed
WO-2008047229-A2 BIARYL ETHER UREA COMPOUNDS PFIZER PRODUCTS INC. (US) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261941-A1 Biaryl Ether Urea Compounds FAAH, FAAH2, LIPC THRB 2969/4885MAPK1 3199/4885L3MBTL1 4652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.